Skip to content

Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Romiplostim in Combination With Low-dose Rituximab and High-dose Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04588194
Enrollment
12
Registered
2020-10-19
Start date
2020-11-01
Completion date
2022-11-01
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura

Keywords

thrombocytopenia

Brief summary

The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, romiplostim and high-dose dexamethasone.

Detailed description

Immune thrombocytopenia is an autoimmune disorder characterized by formation of autoantibodies against platelet antigens leading platelet destruction. Corticosteroids increase the platelet count in about 80 percent of patients. However, many patients have a relapse when the dose of corticosteroid is reduced. Debilitating side effects are common in patients who require long-term corticosteroid therapy to maintain the platelet count. Romiplostim, it is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin, has been shown to be effectively raise the platelet count in adult patients (aged 18 years and over) who have had their spleen removed or where splenectomy is not an option and have received prior treatment with corticosteroids or immunoglobulins, and these medicines did not work (refractory ITP). There are a few case reports where romiplostim an option as first line treatment for IT. The purpose of this study is to determine the response rate and response duration with the combination of rituximab (100 mg weekly four weeks), romiplostim (2mcg/Kg four weekly) and high-dose dexamethasone (40mg PO days 1-4) in untreated adult patients with \<30\*109/L platelet count diagnosed with immune thrombocytopenia. A complete response is defined as an increase in platelet counts to \>150×109/L on two consecutive occasions. A clinical response is defined as an increase in the platelet count between \>30×109/L on two consecutive measures and no bleeding. Duration of response is considered from the day of the initial administration to the first time of relapse (platelet count \<30×109/L) or to time of analysis Patients will be evaluated each week during 4 weeks and then every month for at least 6 months.

Interventions

DRUGRomiplostim

Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21

DRUGRituximab

Rituximab 100 mg weekly days 1, 7, 14, 21

DRUGDexamethasone

40 mg IV/PO days 1-4

Sponsors

David Gomez Almaguer
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Clinically confirmed immune thrombocytopenia (IT) Platelet count less than 30,000/mm3 on two occasions. * Subject ≥ 16 years * Subject has signed and dated written informed consent.

Exclusion criteria

* Previous treatment (only corticosteroids at dose or prednisone equivalent of 300 mg) * Performance status above or equal to 2. * Pregnancy and lactation * Previous splenectomy * Connective tissue disease * Autoimmune hemolytic anemia * Relapse * Active infection, sepsis or fever * Positive for hepatitis B virus or hepatitis C virus or human immunodeficiency virus.

Design outcomes

Primary

MeasureTime frameDescription
Clinical Response28 daysPlatelet counts to \>30×109/L on two consecutive occasions

Secondary

MeasureTime frameDescription
Complete Response28 daysPlatelet counts to \>100×109/L on two consecutive occasions

Countries

Mexico

Contacts

Primary ContactDavid Gómez, MD
dgomezalmaguer@gmail.com83486136
Backup ContactMónica Bustillos, MD
moni.bm88@gmail.com6142255724

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026